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abstract 
Background: Therapeutic advancements due to the introduction of autologous stem cell 
transplantation and ‘novel’ agents have significantly improved clinical outcomes for patients with 
multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns 
about the long-term risk of solid or hematologic second primary malignancies (SPMs). This 
review aims to disseminate the most up-to-date knowledge of possible host-, disease-, and 
treatment-related risk factors for the development of SPMs in patients with MM, and to provide 
practical recommendations to assist physicians. 
Design:A panel of members of the International Myeloma Working Group reviewed the most 
relevant data published in the literature as full papers, or presented at meetings of the American 
Society of Clinical Oncology, American Society of Hematology, European Hematology 
Association, or International Myeloma Workshop up to December 2015. The recommendations 
of the Panel, based on the findings of this literature review, are presented in this paper.  
Results: The published literature indicates that, overall, the risk of SPMs in MM is low, 
multifactorial, and partially related to the length of patients’ survival and MM intrinsic 
susceptibility. Phase III trials and meta-analyses have reported an increase in SPMs when 
lenalidomide is administered to patients either following, or concurrently with, oral melphalan; 
however, the risk of death from MM or adverse events in these patients was significantly higher 
than the risk of death from SPMs. There is also no evidence of increased SPM incidence 
associated with lenalidomide plus high-dose intravenous melphalan, or with bortezomib plus 
oral melphalan, dexamethasone, or thalidomide.  
Conclusion: Based on the available data, the Panel concludes that the potential risk of SPMs 
in MM should not alter the current therapeutic decision-making process. In particular, regimens 
such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to oral 
melphalan plus lenalidomide. 
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key message  
This in-depth review summarizes possible risk factors for second primary malignancies (SPMs) 
in multiple myeloma, and provides practical recommendations. Based on the most recent 
literature data, members of the International Myeloma Working Group conclude that concerns 
about the risk of SPMs, which is low and multifactorial, should not alter the current therapeutic 
decision-making process.  
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introduction 
The potential for solid or hematologic second primary malignancies (SPMs) to develop in 
patients originally diagnosed with multiple myeloma (MM) has long been recognized. Forty-five 
years ago, Dr Robert Kyle and co-workers described the subsequent development of acute 
myeloid leukemia (AML) in four patients who had received prolonged melphalan treatment for 
MM or systemic amyloidosis [1]. Nine years later, other researchers reported a greater-than-
expected incidence of AML (14 cases, 3.8%) among 364 patients with MM who had received 
low-dose melphalan in combination with other alkylating agents [2].  
 
Subsequent Medical Research Council (MRC) studies strengthened the case for a link 
between prolonged exposure to alkylating agents and SPM development in patients with MM, 
reporting 5-, 8-, and 10-year prevalences of myelodysplastic syndromes (MDS) or AML in MM 
patients treated with melphalan or (albeit less consistently) cyclophosphamide of 3%, 10%, and 
20%, respectively [3]. More recently, detailed pathological analysis of myeloid neoplasms 
secondary to MM (mainly MDS or AML) has furnished support for the hypothesis that alkylating 
agents exert a mutagenic effect on the pathogenesis of hematologic SPMs, with evidence of 
complex cytogenetic abnormalities/unbalanced aberrations of chromosomes 5/7 being 
particularly associated with melphalan/cyclophosphamide combinations [4]. 
 
Over the past decade, the successive introduction of high-dose melphalan followed by 
autologous stem cell transplantation (ASCT) as standard initial therapy in younger patients, and 
of the first generations of ‘novel’ agents, such as the immunomodulatory drugs (IMiDs; 
thalidomide and lenalidomide) and the proteasome inhibitor bortezomib, has improved clinical 
outcomes and life expectancy in MM, with current expected median survival ranging from 5 to 8 
years [5–8]. However, increased life expectancy has rekindled concerns about the long-term risk 
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of solid or hematologic SPMs [9–11], particularly as the prognosis of many potential SPMs 
remains very poor in comparison with MM [12–15]. A recent Swedish, population‐based study of 
26,627 patients diagnosed with MM between 1958 and 2011 confirmed a statistically significant 
2.3‐fold (95% confidence interval [CI] 2.1–2.5 ) increased mortality risk in patients with SPMs 
versus a control group of MM patients without SPMs [16]. The randomized, phase III trials 
finding that lenalidomide maintenance therapy is associated with a significantly increased risk of 
SPMs (7%–8%) versus placebo (2%–3%), in both elderly [17] and transplant-eligible patients 
[18, 19], has further added to these concerns [20–22]. 
 
This paper aims to disseminate the latest knowledge of SPM risk factors in patients with 
MM, and provides practical recommendations and guidance to assist physicians in the 
management of patients with MM. In particular, a panel composed of members of the 
International Myeloma Working Group has considered the following questions: 
1. What is the ‘true’ risk of SPM development in patients with MM? 
2. What are the possible host- and disease-related risk factors for SPMs in patients  
with MM? 
3. Do older and novel therapies increase the risk of SPM development in MM? 
The recommendations of the Panel in relation to each of these questions are summarized in 
Table 1, and are presented in detail in the Supplementary Appendix. These recommendations 
are based on the most relevant data published in the literature as full papers (identified through 
the PubMed database) or presented at meetings of the American Society of Clinical Oncology, 
American Society of Hematology, European Hematology Association, or International Myeloma 
Workshop, up to December 2015. 
 
8 
 
what is the ‘true’ risk of SPM development in patients with MM? 
Table 2 summarizes several major population-based, cancer registry studies that investigated 
SPM incidence in patients with MM. These studies generally found no overall increase in SPM 
risk among patients with MM, but did identify an augmented incidence of MDS, AML and, to a 
lesser degree, non-Hodgkin lymphoma (NHL). In contrast, significant heterogeneity in the risk of 
different solid SPM subtypes was observed (Table 2). 
 
It is not easy to draw firm conclusions about the ‘true’ risk of SPMs in MM, or to identify 
specific risk factors in a process that is likely to be multifactorial. Firstly, the estimated overall 
risk reported is relatively small: the cumulative incidence is 1%–10%, which is comparable with 
the incidence of cancer per year of life in the general population [31]. Consequently, some 
reports – particularly of uncontrolled/retrospective and post-hoc studies – may underestimate 
SPMs, as they are not specifically tracked during follow-up. Conversely, over-reporting may 
occur if SPMs are expected to be found in specific arms or subgroups of trials, or when 
appropriate screening is used to prospectively detect early SPMs. In general, well-designed, 
registry-based, population studies, which include individual treatment and long follow-up, may 
be a more effective means of determining therapy-associated SPM risk than some randomized 
trials, which are limited by inclusion and exclusion criteria, lower power, and treatment 
crossover.  
 
Pre-existing or concomitant neoplasms could represent additional confounding factors (see 
below) [32–36]. On the other hand, recent studies indicate that SPM risk may be elevated as a 
‘natural’ consequence of the increased survival achieved with current treatments, rather than as 
a direct result of the therapies themselves [9–11]. 
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Finally, a correct diagnosis of ‘true’ SPM is mandatory. Recently, SPMs occurring in the UK 
MRC Myeloma XI study were reviewed by an ad-hoc independent committee according to pre-
determined criteria [37]. Of 88 reported SPM cases, only 67 (76%) were confirmed as trial-
related SPMs; the remaining cases were rejected because of: evidence that the second 
malignancy pre-existed prior to trial enrollment (57%); no evidence of malignancy found on 
further investigation (24%); reported non-malignant skin conditions (14%); and spontaneous 
resolution of cytopenias upon cessation of treatment (5%).  
  
what are the possible host- and disease-related risk factors for SPMs 
in patients with MM? 
 
SPM development is likely multicausal. In addition to specific treatments, possible risk factors 
may be classified as either host- or disease-related. 
 
host-related risk factors 
age and sex. Among potential host-related factors, older age and male sex have most 
commonly been associated with increased SPM incidence in patients with MM [18, 26, 38, 39]. 
Nevertheless, there are inconsistencies in the published data. Updated data from the 
Surveillance, Epidemiology, and End Results (SEER) program, for example, showed a decrease 
in total SPM risk with increasing age: MM patients <65 years of age had a 5-fold increased risk 
of developing AML versus those aged >75 years) [27]. Meanwhile, women with MM were found 
to be at significantly increased risk of leukemia versus men [27]. 
 
ethnicity. Several SEER-based analyses demonstrate an impact of ethnicity on the risk of SPM 
development in patients with MM [26, 40]. In an analysis of 2021 patients with MM and SPMs 
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(diagnosed between 1973 and 2008), Hispanic whites had a significantly decreased 
observed/expected (O/E) risk of developing overall (O/E 0.67; 95% CI 0.50–0.88), all solid-
organ (0.66; 95% CI 0.48–0.89), lung/bronchus (0.34; 95% CI 0.08–0.88), and prostate SPMs 
(0.48; 95% CI 0.19–0.99). Non-Hispanic whites showed an increased O/E risk of developing 
melanoma of the skin (1.38; 95% CI 1.06–1.78), NHL (1.28; 95% CI 1.01–1.61), and AML (6.85; 
95% CI 5.55–8.38). The O/E risk of developing SPMs of the kidney/renal pelvis (O/E 2.17; 95% 
CI 1.31–3.39) and AML (6.24; 95% CI 3.41–10.47) was increased among African Americans. 
The O/E risk of AML as a SPM was also found to be significantly increased among Asian Pacific 
Islanders (6.32; 95% CI 1.72–16.19) [40].  
 
genetics. Genetic alterations and their interaction with environmental factors and/or therapy may 
contribute to familial and individual predisposition to MM and, possibly, to different SPMs [41–
43]. Genotype studies have shown that germline mutations in the CDKN2A gene may 
predispose to both MM and other cancers [41]. Furthermore, the G/G phenotype of single 
nucleotide polymorphism (SNP) rs1617640 in the erythropoietin promoter gene has been found 
to be more common in individuals with MM who develop MDS versus those who do not [44], 
thus confirming a potential role for susceptibility genes in the development of SPMs in these 
patients. Other genetic polymorphisms have been found to be associated with an increased risk 
of MM [45], while conversely appearing to protect against potential solid SPMs, including 
prostate cancer [27, 46]. Genome-wide association studies and gene expression microarray 
analysis of groups of patients with or without SPMs have identified several other candidate 
SNPs that are associated with acute leukemia after other neoplasms [47, 48]. Studies 
investigating baseline whole bone marrow gene-expression profiling, proteomic analyses, and 
SNPs are currently ongoing, with the aim of identifying patients who may have a marked 
propensity to develop SPMs [43]. 
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prior cancer. Studies have shown that prior or synchronously different malignancies (PSMs) are 
more common than SPMs in MM, occurring in 3%–24% of patients and thus representing a 
possible confounding factor when a diagnosis of SPM is suspected [33, 35, 36, 49–51]. While 
these tumors are often early-stage or good-prognosis neoplasms, the largest group (up to 90%) 
of invasive PSMs comprises prostate, gastric, colorectal, and breast cancers, while fewer 
hematologic malignancies (10%–27%) have been reported.  
 
Patients with PSMs frequently have a history of chemotherapy, radiotherapy, and/or 
hormone therapy, which confers a poor prognosis. In these patients, MM potentially occurs as a 
SPM. Interestingly, in a large Swedish study, MM patients with PSMs at diagnosis were not at 
increased risk of developing a subsequent SPM versus MM patients without PSMs (overall 
response 1.19; 95% CI 0.97–1.46) [52]. These findings suggest that patients with MM and a 
PSM should not be denied the best available therapy because of fears of SPM development. 
 
additional individual factors. Many additional socio-economic, occupational, lifestyle, and 
environmental factors could potentially play a role in the development of both SPMs and primary 
cancers. The potential involvement of such factors in the context of competing risks may be 
difficult to differentiate, especially if their real impact on the development of SPMs is small; 
consequently, no firm data have yet been produced in the setting of MM [10, 11, 53].  
 
disease-related risk factors 
That MM by itself (independent of MM therapy) may be a risk factor for SPM development was 
first hypothesized nearly 40 years ago [54]. Since then, baseline plasma cell cytogenetics, 
disease stage, and some MM subtypes have been associated with increased SPM incidence. 
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Interestingly, the risk of developing MDS/AML appears significantly increased in individuals with 
monoclonal gammopathy of undetermined significance (MGUS) versus the general population. 
For example, in a large, Swedish, population-based study, the risk of MDS/AML was increased 
8-fold in the subset of 2293 patients with IgG or IgA isotype MGUS versus age- and sex-
matched individuals from the general population [24]. Risk levels were increased in patients with 
raised M-component concentrations >1.5 g/dl versus those with lower levels, suggesting that 
the risk of MDS/AML development in MGUS patients with more extensive/advanced disease is 
similar to that in patients with symptomatic MM. An excess risk of non-melanoma skin cancer in 
MGUS, similar to that observed in symptomatic MM, was also seen.  
 
A Mayo Clinic study systematically screened 17,315 individuals for the presence of MGUS 
[55]. Of the 605 patients found to have MGUS, seven were subsequently diagnosed with MDS, 
and two with AML (one of whom had antecedent MDS). Compared to 16,710 non-MGUS 
controls, these MGUS patients had a 2.4-fold significantly increased risk of developing MDS; the 
risk of AML was slightly, but not significantly, increased. No cases of acute lymphoblastic 
leukemia (ALL) were seen in the MGUS cohort. In a subanalysis, MDS occurred in patients with 
all Ig isotypes (including IgM), while AML was observed only in patients with IgA/IgG. Such 
results were not changed when ‘early’ MDS/AML patients, diagnosed within the first year 
following diagnosis of MGUS, were excluded.  
 
Despite differences in study design and number of MGUS patients included, the Swedish 
and Mayo clinic findings both suggest a possible intrinsic causal role for plasma cell disorders, 
and a consequent inherent increased risk of MDS/AML that is independent of MM therapy. 
Recently, however, International Staging System stage and history of smoldering myeloma or 
MGUS were found to have no impact on SPM occurrence in a large, US disease registry study 
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[29]. Interestingly, plasma cell cytogenetic abnormalities were linked with an increased 
incidence of SPMs in symptomatic MM (hazard ratio [HR] = 1.64, P < 0.05), when modeled from 
study enrollment in the Total Therapy (TT) trials [56]. Furthermore, three of the patients who 
ultimately developed MDS/AML in the lenalidomide arm in the MM-015 trial were part of a group 
of 11 patients with plasma cell complex cytogenetics at baseline [57]. In contrast, predominantly 
favorable cytogenetics have been reported in patients who develop SPMs, suggesting that less 
aggressive MM and long disease latency may favor the manifestation of additional malignancies 
[30].  
 
Tumor-induced immunodeficiency, deregulated release of cytokines, chronic inflammation, 
and common tumor cell precursors may also play an important role in increasing the 
susceptibility of MM patients to SPM development [58]. Immunologic defects may include 
quantitative and functional abnormalities in T-cell and B-cell compartments, natural killer and 
dendritic cell populations, and neutrophils, as well as abnormal cytokine production, modified 
membrane antigen/receptor expression, and impaired phagocytosis. Additionally, the possibility 
of transforming MM into a chronic entity, with multiple relapses and salvage therapies using 
older and newer drugs in sequence, may result in cumulative immunosuppression/dysfunction, 
further compromising immune surveillance against tumor cells. This could play a particularly 
significant role in increasing the risk of various skin cancers, including melanoma. MM 
pathogenesis could also modify sex hormone levels, which could explain the decreased risk of 
some hormone-related solid SPMs – including breast and prostate cancer – that is seen in MM. 
However, less frequent screening after MM diagnosis is another possible explanation for the 
reported reduced risk of these solid SPMs [27].  
 
do older and novel therapies increase SPM risk in MM?  
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Early studies identified that prolonged exposure to melphalan increases the risk of hematologic 
SPM development (in particular, MDS/AML) in patients with MM, likely as a result of a direct 
mutagenic effect inducing DNA damage [1–4]. The MM treatment paradigm has evolved 
significantly over the past few years, and numerous studies have continued to investigate 
treatment-related risk factors for SPMs. The characteristics and findings of the key retrospective 
studies and prospective first-line phase III randomized trials that have gathered information on 
the impact of various anti-myeloma treatments on SPM incidence in patients with MM are 
summarized in Tables 3 and 4, respectively.  
 
radiotherapy 
Radiation dose and extended fields are supposed, but not well proven, factors favoring SPM 
development in patients with MM. Indeed, several solid SPMs have been described in MM 
patients following combination chemo-radiotherapy [10, 24, 49, 56]. However, compared with 
other malignancies in which loco-regional radiation treatments may induce SPMs in surrounding 
tissues (including bone marrow), information about the exact role of radiotherapy and risk of 
SPMs in MM is currently limited. Recent US Connect MM registry data did not support a 
possible relationship between radiotherapy and SPM incidence [29]; this could be due to the 
lower radiotherapy dose usually administered to patients with MM.  
 
ASCT 
Data suggest that secondary MDS/AML risk is increased following ASCT in patients with 
lymphoma (14.5% cumulative incidence up to 15 years) [72]. This risk is increased further by 
older age, male sex, obesity, and pre-transplant treatment with alkylating agents [13, 38]. In 
contrast to lymphoma patients, however, studies have found no significant increase in SPM 
incidence following ASCT in patients with MM [24, 27, 38, 73]. In particular, a recent 
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retrospective study in the USA found a similar incidence of new cancers in a large auto-
transplantation cohort to that in age-, race-, and gender-adjusted comparison subjects, with an 
O/E ratio of 1.00 (99% CI 0.81–1.22) [38]. 
 
SPM rates in patients with MM post-ASCT may be attributable to ‘conventional’, alkylating 
agent-incorporating therapy prior to transplantation, rather than to the myeloablative therapy 
itself. For example, while investigating the possible role of high-dose melphalan in augmenting 
the risk of secondary MDS/AML in MM patients, Govindarajan et al. [61] observed seven MDS 
cases in 117 patients who had received extended courses of chemotherapy prior to tandem 
ASCT, whereas no cases were observed among 71 patients who received limited chemotherapy 
before ASCT [61]. The authors concluded that preceding treatments, and not conditioning with 
high-dose melphalan, were the likely cause of MDS post-ASCT. 
 
 The low risk of SPM development after ASCT in MM versus lymphoma patients may be 
partially explained by the earlier use of transplants in MM, the attention paid to avoiding pre-
transplant stem-cell-damaging agents, and the cessation of total body irradiation during 
conditioning [74]. 
 
novel agents 
IMiDs: thalidomide and lenalidomide. Initial population studies found no relationship between 
SPM incidence in MM and treatment with novel agents, including thalidomide and lenalidomide 
[24, 27, 60]. However, these studies were limited by a short follow-up period, lack of focus on 
SPMs, and the non-uniform use of novel agents during their first few years of availability. 
Several major studies have since indicated that lenalidomide may increase SPM risk, 
particularly in the maintenance setting [75]. These studies include three large, phase III, 
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placebo-controlled, randomized trials (IFM 2005-002, CALGB 100104, MM-015), all of which 
reported a significantly increased incidence of SPMs in newly diagnosed patients with MM who 
received lenalidomide maintenance versus similar patients who did not receive lenalidomide 
maintenance after either ASCT [18, 19, 76] or induction therapy [17, 77]. A recent update to 
CALGB 100104 confirmed that lenalidomide maintenance post-ASCT continued to be 
associated with an increased risk of SPMs versus placebo [78]; however, a post-hoc survey of 
this study raised the possibility that the entire patient population may have had an inherent risk 
for other malignancies, owing, at least in part, to risk factors such as age, prior tumors, prior 
therapies, and family history [50]. Interestingly, secondary ALL after lenalidomide treatment have 
been reported only rarely [18, 79]. 
 
A 2014 meta-analysis of seven randomized, controlled, phase III clinical trials that included 
lenalidomide as first-line therapy reported increased hematologic SPM incidence in newly 
diagnosed MM patients: 32/2620 (1.2%) versus 3/598 (0.5%) in patients treated (+L) or not 
treated (–L) with lenalidomide [39]. The cumulative incidence at 5 years was 3.1% (95% CI 1.9–
4.3%) in the +L group versus 1.4% (95% CI 0.0–3.6%) in the –L group. In +L patients, SPM 
incidence increased linearly over time, and was significantly higher than in –L patients (HR = 
3.8, 95% CI 1.15–12.62, P = 0.029). Co-exposure to lenalidomide and oral melphalan appeared 
to be the main driver of increased hematologic SPM risk (5-year cumulative incidence 3.9%), 
while lenalidomide plus cyclophosphamide (not estimable), lenalidomide alone (1.3%), and 
melphalan alone (1.4%) had no impact. The hematologic SPM risk associated with the 
combination of oral melphalan plus lenalidomide was also significantly increased versus 
intravenous melphalan and lenalidomide. In comparison with the situation in relation to 
hematologic SPMs, the distribution of solid SPMs was similar in +L and –L groups, with the 
exception of urinary tract tumors, which were more common in the +L group. This latter finding 
may be a consequence of the renal excretion of lenalidomide. Finally, it is worth noting that, in 
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the +L group, the risk of SPM-related mortality (2.4%) was significantly lower than the risk of 
death owing to either MM (26.5%) or treatment-related adverse events (9.8%) [39]. 
 
Several other studies have also suggested that, in patients with either newly diagnosed or 
relapsed/refractory MM, SPM risk may be increased with lenalidomide plus oral melphalan, but 
not with lenalidomide plus cyclophosphamide [80, 81] or dexamethasone [36, 64–66, 82]. As no 
increase in SPM incidence has been reported with lenalidomide in combination with 
dexamethasone, even on prolonged administration [66], a possible ‘protective’ effect of this drug 
might be considered. Different melphalan dose [67] and/or lenalidomide dosing schedules (3 
weeks on, 1 week off versus continued treatment) could explain the lack of increased SPM 
incidence in some studies of lenalidomide maintenance therapy.  
 
The actions of lenalidomide are complex, and the mechanism(s) by which it might favor 
SPM development remain undefined. Lenalidomide’s immunosuppressive activity, and its effects 
on the tumor microenvironment, may favor the escape/growth of abnormal clones that could 
result in the development of SPMs. Alternatively, treatment-related MDS/AML might be caused 
by a possible damaging stem-cell effect of lenalidomide. Cereblon, a molecular target for the 
anti-MM activity of lenalidomide, is a component of the E3 ubiquitin-ligase complex that is 
essential for nucleotide excision repair [83]. Inhibition of cereblon/DDB1 complex by 
lenalidomide impairs repair mechanisms after melphalan-induced DNA damage, and could 
therefore facilitate the development of SPMs [83].  
 
Analysis of data from the TT2 trial showed a trend for increased solid SPM risk from the 
initiation of maintenance therapy in the TT plus thalidomide maintenance versus the TT without 
thalidomide arm [56]. This suggests an IMiD class effect, rather than a lenalidomide-specific 
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effect, associated with alkylator exposure. However, the absence of a randomized comparison 
and the number and variety of drugs used in the TT trials make it difficult to determine whether 
the thalidomide-associated increased SPM risk in TT2 is of similar magnitude to that seen with 
lenalidomide (see below). 
 
bortezomib. Studies conducted to date indicate that bortezomib is associated with a low risk of 
SPM development. For example, after 54 months’ follow-up, SPM incidence in elderly patients 
with MM who were treated with VMPT-VT (a four-drug combination comprising bortezomib, 
melphalan, prednisone, and thalidomide, followed by maintenance treatment with bortezomib 
plus thalidomide) was 0.9% versus 1.5% in similar patients treated with VMP (bortezomib, 
melphalan, and prednisone) [69]. In the phase III VISTA trial in patients with previously 
untreated MM, incidences of hematologic and solid tumor SPMs after 60.1 months’ follow-up did 
not differ significantly between patients treated with VMP (1% and 5%, respectively) versus 
those treated with melphalan plus prednisone (1% and 3%, respectively), and were consistent 
with background rates [70]. 
 
Mature data on the incidence of SPMs were recently available for 299 patients enrolled in 
the phase III, multicenter, GIMEMA 26866138-MMY-3006 clinical trial that compared 
bortezomib, thalidomide, and dexamethasone (VTD) versus thalidomide plus dexamethasone 
(TD) as induction before, and consolidation after, a double ASCT [71]. The proportion of patients 
who developed SPMs was lower in the VTD (5%) than in the TD arm (11%, P = 0.068). Among 
those patients who developed SPMs, solid (75% versus 71%) and hematologic (25% versus 
29%) SPM rates were similar in the two arms. In the overall population, SPM incidence was 
significantly reduced at 6 years among patients randomized to VTD versus TD (6% versus 13%; 
P = 0.037). When the analysis was performed according to SPM type, no statistically significant 
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difference could be demonstrated. These data suggest that bortezomib may be associated with 
a low risk of SPM development, and that this particular drug may even decrease the risk of 
SPMs due to thalidomide when used in combination. A large, single-institution, registry analysis 
of host-, myeloma-, and treatment-specific risks for SPMs in 744 consecutive MM patients 
recently confirmed that cumulative incidence rates for SPMs were decreased in bortezomib-
treated patients [30].  
 
other novel agents. Consolidated data examining the SPM risk associated with the second-
generation proteasome inhibitor carfilzomib, the third-generation IMiD pomalidomide, and the 
histone-deacetylase inhibitor panobinostat are not yet available. However, none of the studies 
published to date reported an increased SPM risk in patients treated with these drugs [84–91]. 
In particular, the combination of carfilzomib, lenalidomide, and dexamethasone was not 
associated with an increased incidence of SPMs in relapsed MM (2.8%) versus lenalidomide 
plus dexamethasone (3.3%) [90].   
 
SPM development following treatment with monoclonal antibodies was investigated in a 
recent phase III trial comparing the combination of elotuzumab (an anti-SLAMF7 monoclonal 
antibody), lenalidomide, and dexamethasone (elotuzumab group) versus lenalidomide plus 
dexamethasone (control group) in patients with relapsed or refractory MM [92]. SPMs 
developed in 35 of the 635 patients treated (5.5%): 22 (6.9%) in the elotuzumab group and 13 
(4.1%) in the control group, without significant differences between the rates of hematologic 
SPMs and second solid tumors. After adjustment for exposure to study therapy, the second 
primary cancer incidence rate per 100 patient-years was 3.5 in the elotuzumab group versus 2.8 
in the control group. No increase in SPM incidence was reported in a phase I study of single-
agent daratumumab (an anti-CD38 monoclonal antibody) in MM [93]. 
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summary  
SPMs represent a relatively small, but clinically relevant, issue that must be considered and 
managed within the current treatment paradigms available to patients with MM. For individual 
patients with MM in whom a secondary hematologic or solid tumor is diagnosed, the clinical and 
psychological consequences may, indeed, be devastating. These two parallel perspectives (‘on 
average’ versus ‘individual patients’) should be carefully taken into consideration by any 
physician. Our goal should be to significantly reduce the impact of SPMs on MM patients by 
clarifying the biologic mechanisms involved, identifying associated risk factors, improving 
understanding of clinical behavior, and applying appropriate preventive strategies. 
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tables 
Table 1. Panel recommendations 
Recommendation 
What is the ‘true’ risk of SPM development in patients with MM? 
• Well-designed, population-based studies suggest that the risk of SPMs in MM is low, and is partially related to the lengthening survival of patients with MM 
• The risk of SPMs should be evaluated in individual patients, according to patient-, disease-, and treatment-related factors  
• Additional and systematic data gathering is needed to determine the incidence and types of SPMs in patients with MM currently treated both in clinical trials and in the real-world 
setting 
• Ongoing trial protocols should be amended to include enhanced monitoring and precise measurement of secondary cancers (including non-invasive neoplasms), and include 
SPMs as an ‘a priori’ well-defined endpoint. These measures should be integral to the design of any future prospective clinical trials 
• Prospective population-based studies gathering information on the baseline characteristics and treatment of individual patients should also report SPM data 
• SPM data collected in clinical trials and observational studies should include details of the time to development, clinical and biologic characteristics, prognosis, and natural history 
of SPMs observed 
• SPM incidence rates should be adjusted for person-years at risk (that is, rate per 100 person/years) 
• Specific routine screening for SPMs, beyond that suggested for the general population, is not recommended. However, diagnostic measures that would aid the detection of 
suspected SPMs during daily clinical work-up should be considered, on a case-by-case basis, in long-term MM survivors. In particular, bone marrow examination with cytogenetic 
analyses (or FISH, if necessary) is recommended at baseline and in the event of unexplained blood count abnormalities in the real-life setting and in prospective observational 
and investigational studies 
• Every SPM case should be reviewed carefully to accurately assess the true impact of treatment on SPM development, and to prevent false inflation of reported SPM rates 
What are the possible host- and disease-related risk factors for SPMs in patients with MM? 
• The pathogenesis of SPMs in MM is likely to be multifactorial 
• Biologic samples from all MM patients included in clinical trials and, when possible, encountered in clinical practice, should be collected and stored for genetic analysis. Ideally, 
samples should yield DNA for genomic analysis or, better still, RNA for gene expression profiling. Collection of germline and tumor-related material, and re-banking of biologic 
samples during the course of the disease, are also recommended 
• Next-generation sequencing genomic studies designed to identify genetic profiles associated with increased SPM risk should be planned 
Do older and novel therapies increase the risk of SPM development in MM? 
• Based on the available evidence, the potential risk of SPMs in MM should not alter the current therapeutic decision-making process 
• Data regarding the use of ASCT in MM are reassuring, and the Panel recommends that first-line therapeutic approaches in eligible MM patients should always include ASCT 
conditioned with high-dose intravenous melphalan 
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• For the current approved indication of lenalidomide in the treatment of relapsed MM, the benefits of therapy clearly outweigh any risk of SPMs 
• Similarly, in front-line therapy without concurrent oral melphalan, regimens such as lenalidomide plus dexamethasone (or alternatives such as cyclophosphamide or alkylating-
free combinations) remain safe and effective options that should be considered for patients with MM, instead of oral melphalan in combination with lenalidomide 
• In the maintenance setting, prolonged administration of lenalidomide where there is antecedent melphalan exposure should generally be avoided, with the important exception of 
high-dose melphalan used as a conditioning regimen for ASCT 
• All patients initiating lenalidomide maintenance should undergo a baseline bone marrow examination with cytogenetics to ensure that there is no overt evidence of dysplasia or 
concerning cytogenetic abnormalities. There should also be a low threshold for careful bone marrow analysis with karyotyping for patients with unexplained cytopenias that 
persist despite lenalidomide withdrawal 
• In cases where the overall survival benefit of maintenance therapy with lenalidomide is still not well established, the risks versus any possible benefits of treatment should be 
considered carefully 
• The potential increased risk of SPMs should be adequately addressed through appropriate discussion with the patient with MM, bearing in mind current knowledge about 
treatment-associated risks and benefits 
• Physicians should remain well informed about the latest data on the risk of SPMs in MM 
ASCT, autologous stem cell transplantation; FISH, fluorescence in situ hybridization; MM, multiple myeloma; SPM, secondary primary malignancies.  
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Table 2. Key population-based registry studies evaluating the incidence of SPMs in patients with MM 
Authors Type of 
study 
Study 
period 
Patients 
(N) 
All SPMs 
(n, %) 
Hematologic 
SPMs  
(n, %) 
Solid tumor 
SPMs  
(n, %) 
Time from MM 
diagnosis to SPM 
development  
(median) 
All SPMs  
SIR  
(95% CI) 
Hematologic SPMs  
SIR  
(95% CI) 
Solid tumor SPMs 
SIR  
(95% CI) 
Dong et al. 
[23] 
Population-
based  
registry 
study 
1958–
1996 
8656 475  
(5.5) 
83  
(1.0) 
392  
(4.5) 
2.9 y NR All HMs 2.19  
(1.74–2.71); 
NHL 1.74  
(1.12–2.57); 
AML 8.19  
(5.70–11.4) 
All STs 0.81  
(0.70–0.90) 
Mailankody 
et al.  
[24] 
Population-
based  
registry 
study 
1986–
2005 
8740 577  
(6.6) 
69  
(0.8) 
508  
(5.8) 
45.3 mo  
MDS/AML 
All SPMs 1.26  
(1.16–1.36) 
All HMs 2.04  
(1.59–2.58);  
AML/MDS 11.51 
(8.19–15.74) 
All STs 1.19  
(1.09–1.30); 
GI 1.30 (1.09–1.53);  
NMST 2.22  
(1.74–2.80) 
Youlden  
et al.  
[25] 
Population-
based  
registry 
study 
1982–
2001 
2174 134  
(0.6) 
NR NR NR Males 1.04  
(0.84–1.27); 
females 0.89  
(0.64–1.21) 
NR NR 
Chakraborty 
et al.  
[26] 
Selected 
population 
of MM 
patients 
with SPMs 
1973–
2008 
3245 
patients 
with MM 
as first of 
≥ SPM 
1657  
(51.1) 
214  
(6.6) 
1394 
(43.0) 
NR All SPMs 0.99  
(0.95–1.04) 
All HMs 1.68  
(1.46–1.92); 
all leukemias 3.07 
(2.57–3.64); 
ALL 5.48 (NR); 
AML 7.01 (NR); 
CML 2.26 (NR) 
All STs 0.94  
(0.89–0.99); 
hypopharynx 0.0 
(NR); 
esophagus 0.35 (NR); 
breast 0.76  
(0.63–0.90); 
prostate 0.75 (NR);  
small intestine 2.03; 
skin, excluding  
basal/squamous 
carcinomas 1.43 
(1.09–1.85); 
kidney 1.51  
(1.13–1.98); 
KS 3.3 (1.06–7.69) 
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Razavi  
et al. [27] 
Population-
based  
registry 
study 
1973–
2008 
36,491 2026, 
including 
56 
miscellan
eous 
(5.5) 
263  
(0.7) 
1707 (4.7) 5.2 y All SPMs: 0.98 
(0.94–1.02) 
All HMs 1.63  
(1.45–1.84); 
AML 6.51  
(5.42–7.83); 
NHL 1.28  
(1.04–1.57) 
All STs 0.92  
(0.88–0.97); 
esophagus 0.49 
(0.28–0.87); 
lung 0.88  
(0.78–0.99); 
breast 0.81  
(0.69–0.94);  
prostate 0.69  
(0.61–0.77);  
melanoma 1.36 
(1.07–1.74); 
urinary bladder 1.22 
(1.03–1.44);  
kidney/renal pelvis 
1.30 (1.01–1.66);  
thyroid 1.63 
 (1.05–2.52) 
Tzeng  
et al. [28] 
Population-
based  
registry 
study 
1997–
2009 
3970 71  
(1.8) 
35  
(0.9) 
36  
(0.9) 
1.9 y NR All HMs 13.0  
(7.79–21.6);  
NHL 7.72  
(3.83–15.6);  
AML 23.9  
(10.5–54.5) 
All STs 0.57  
(0.40–0.79);  
lung 0.28  
(0.09–0.87) 
Rifkin  
et al. [29] 
US MM 
Registry 
study 
2009–
2012 
1493 
enrolled, 
1443 
treated 
74 (5.1); 
invasive 
51 (3.5); 
NMST 26 
(1.8%) 
14  
(1.0) 
37  
(2.6) 
NR Incidence per 
100/patient-y in 
977 patients +L: 
invasive: 0.85  
(0.61–1.19); 
incidence per 
100/patient-y in 
466 patients -L: 
invasive: 1.16  
(0.72–1.86) 
Incidence per 
100/patient-y in 977 
patients +L: 
invasive HMs: 0.17 
(0.08–0.36); 
incidence per 
100/patient-years in 
466 patients -L:  
invasive HMs: 0.47 
(0.22–0.99) 
Incidence per 
100/patient-y in 977 
patients +L:  
invasive STs: 0.67 
(0.46–0.98); 
NMST 0.50  
(0.32–0.77); 
incidence per 
100/patient-y in 466 
patients -L:   
invasive STs: 0.68 
(0.36–1.26); 
NMST 0.41  
(0.18–0.91) 
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Engelhardt 
et al.  
[30] 
Friburg 
University 
Registry 
study 
1997–
2011 
744 49  
(6.6) 
17  
(2.3) 
32  
(4.3) 
NR NR NR NR 
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; CML, chronic myeloid leukemia; GI, gastrointestinal; HM: hematologic malignancy; KS, 
Kaposi’s sarcoma; +L, exposure to lenalidomide; -L, no exposure to lenalidomide; MDS, myelodysplastic syndromes; MM, multiple myeloma; mo, months; NHL, non-Hodgkin 
lymphomas; NMST, non-melanoma skin tumors; n, number; NR, not reported; SIR, standardized incidence rate; SPM, secondary primary malignancy; ST, solid tumor; y, years. 
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Table 3. Key retrospective studies that evaluated SPM incidence in patients with MM 
Authors Type of study Study period 
(median 
follow-up) 
Patients 
(N) 
All SPMs  
(n, %) 
Hematologic 
SPMs  
(n, %) 
Solid tumor  
SPMs  
(n, %) 
Time from MM 
diagnosis to SPM 
development 
(median) 
Additional information 
Cuzick  
et al. [3] 
Retrospective 
study based 
on clinical 
trials (MRC) 
1964–1975 648 12  
(1.9) 
12  
(1.9)  
MDS, AML 
NR 82 mo Actuarial prevalence 3%, 10%, and 20% at 
5, 8, and 10 y, respectively 
Finnish 
Leukemia 
Group [15] 
Retrospective 
study based 
on clinical 
trials 
1979–1985  
(16 y)  
432 40  
(9.3) 
17  
(3.9)  
AML, NHL 
23  
(5.3) 
37 mo ST; 
56 mo AML 
O/E ratio 45.6 for AML, P < 0.001;  
4.29 for NHL, P = ns;  
0.75 for STs, P = ns 
Munker  
et al. [35] 
Retrospective, 
single-center 
study 
1995–2010 197 5  
(2.5) 
1  
(0.5) 
4  
(2.0) 
NR IR of SPMs or subsequent cancers: 2%, 
4.8%, and 11.9% at 3, 5, and 10 y, 
respectively. 34 additional malignancies 
were diagnosed before MM diagnosis was 
made 
Przepiorka  
et al. [59] 
Retrospective, 
single-center 
study, ASCT 
1996–2005 82 10  
(12.2) 
10  
(12.2)  
MDS 
NR 50 mo 5-y cumulative incidence 18% 
Barlogie  
et al. [32] 
Retrospective, 
single-center 
study, ASCT 
1989–2007 2418 26  
(1.1) 
26  
(1.1)  
MDS, AML 
NR NR 72 patients with transient MDS-associated 
cytogenetic abnormalities 
Grudeva-
Popova [33] 
Retrospective, 
single-center 
study 
1990–2010 332 5  
(1.5) 
NR NR 6.6 y Most additional cancers were present before 
the diagnosis of MM. Higher incidence of 
SPMs associated with longer survival 
Hasskarl  
et al. [49] 
Retrospective, 
single-center 
study 
1997–2008 589 18  
(3.1) 
6  
(1.0)  
MDS, AML, 
NHL 
12  
(2.0)  
50% lung and 
prostate cancers 
35 mo IR 7.8%, 10.3%, and 11.6%, at 2, 5, and 10 
y, respectively 
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Usmani  
et al. [56] 
Retrospective, 
single-center 
study with 
multiple 
protocols 
1998–2009 1148 73  
(6.4) 
36  
(3.1) 
MDS, AML, 
NHL, ALL 
37  
(3.2) 
Prostate, NMST, 
breast, thyroid, 
bladder, colon,  
renal, lung 
NR HR = 0.63–1.30 (95% CI 0.18–2.67),  
without significant differences according to 
type of SPM (HMs or STs) or time of 
evaluation (enrollment vs maintenance) 
Fenk  
et al. [60] 
Retrospective, 
single-center 
study, ASCT 
1994–2009 313 18  
(5.8) 
9  
(2.8)  
MDS, AML, HL 
9  
(2.8)  
Breast, lung, others 
56 mo Cumulative incidence 19.7%; IR 0.7%, 5.8%, 
and 15.7% at 2, 5, and 10 y, respectively 
Srivastava  
et al. [36] 
Retrospective, 
single-center 
study (LD, 
ASCT 50%) 
2003–2011 
(4.2 y)  
286 21  
(6.6) 
2  
(0.7)  
AML 
19  
(6.6; 10 [3.5], 
excluding NMST) 
Melanoma, breast, 
others 
44 mo 21 (9) SPMs/1120 person-y of follow-up from 
MM diagnosis  
Govindaraja
n et al. [61] 
Retrospective, 
single-center 
study, ASCT 
NR  188 7  
(3.7) 
7  
(3.7)  
MDS 
NR 63 mo Prolonged CT before ASCT correlated with 
evidence of SPMs 
Ormerod  
et al. [62] 
Retrospective, 
single-center 
study, ASCT 
1990–2010 
(2995 d) 
279 10  
(3.6) 
2  
(0.7) 
MDS, ALL 
8  
(different types) 
360 d 9 SPMs in patients +L 
Rollison  
et al. [63] 
Retrospective 
cohort study 
with nested 
case-control 
analysis  
(+L vs -L)  
2004–2012 
(40 mo)  
1653 51  
(3.1) 
14  
(0.8) 
8 +L vs 6 -L 
37  
(2.2) 
9 +L vs 28 -L;  
14 different types 
NR IR of SPM 0.55 per 100 person-y with +L and 
1.27 per 100 person-y with -L;  
HR = 0.44 (95% CI 0.24–0.80); 
HMs HR = 0.90 (95% CI 0.31–2.63); 
STs HR = 0.55 (95% CI 0.15–0.69) 
Dimopoulos  
et al. [64] 
Retrospective, 
pooled 
analysis of 11 
clinical trials in 
RRMM treated 
with 
lenalidomide 
2002–2008 3846 52  
(1.3) 
8  
(0.2)  
MDS, NHL, 
AML 
44  
(1.1) 
  Overall IR of SPMs, including non-invasive 
skin cancers: 3.62. IR of invasive (both HMs 
and STs) SPMs: 2.08 (95% CI 1.60–2.60) 
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Dimopoulos  
et al. [64] 
Retrospective, 
pooled 
analysis of 2 
phase III 
randomized 
trials (LD vs 
placebo-dex) 
2003–2008 703 23  
(3.3) 
2  
(0.3)  
MDS (in +L) 
17 (2.4) in 
+L (11 NMST); 
4 (0.6) in -L (2 NMST) 
1–45 mo Overall IR of SPMs: 3.98 (95% CI 2.51–6.31) 
in +L vs 1.38 (95% CI 0.44–4.27) in -L;  
IR of NMST: 2.40 (95% CI 1.33–4.33) in +L 
vs 0.91 (95% CI 0.23–3.66) in -L;  
IRs of invasive SPMs: 1.71 (95% CI 0.86–
3.43) in +L vs 0.91 (95% CI 0.23–3.66) in -L 
Mahindra  
et al. [38] 
Retrospective 
analysis in 
patients 
receiving 
ASCT 
1990–2010 4161 163  
(3.9) 
O/E ratio 5.19 
(99% CI 1.67–
12.04;  
P = 0.0004)  
for AML 
O//E ratio 3.58  
(99% CI 1.82– 
6.29;  
P < 0.0001) for 
melanoma 
NR Crude IR 1.2 per 100 person-y; cumulative 
incidences of 2.6% (95% CI 2.09– 3.17), 
4.2% (95% CI 3.49–5.00), and 6.1% (95% CI 
5.08–7.24) at 3, 5, and 7 y, respectively 
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; CI, confidence interval; CT, chemotherapy; d, days; HL, Hodgkin lymphoma; 
HM, hematologic malignancy; HR, hazard ratio; IR, incidence rate; +L, exposure to lenalidomide, -L no exposure to lenalidomide; LD, lenalidomide plus dexamethasone; MDS, 
myelodysplastic syndromes; MM, multiple myeloma; mo, months; MRC, Medical Research Council; NHL, non-Hodgkin lymphomas; NMST, non-melanoma skin tumors; NR, not reported; 
ns, not significant; O/E ratio, observed-to-expected ratio; RRMM, relapsed/refractory multiple myeloma; SPM, secondary primary malignancy; ST, solid tumor; y, years. 
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Table 4. Key first-line phase III trials that evaluated SPM incidence in MM patients  
Author
s 
Type of study Study 
period 
(median 
follow-up) 
Enrolled patients  
(N) 
All SPMs  
(n, %) 
Hematologic 
SPMs  
(n, %) 
Solid tumor 
SPMs  
(n, %) 
Time from MM 
diagnosis to SPM 
development 
(median) 
Additional information 
Bergsagel  
et al. [2] 
Comparison of 
different alkylating 
agent-based 
regimens 
1973–1977 364 14  
(3.8)  
AML 
14  
(3.8) 
NR NR Actuarial risk of AML rapidly increased 
to 17.4% at 50 mo 
Attal  
et al. [18] 
Lenalidomide 
consolidation 
followed by 
lenalidomide vs 
placebo as 
maintenance after 
ASCT 
2006–2008 614  
(6 did not receive 
randomized 
treatment)  
(306 +L vs  
302 -L) 
All SPMs: 32 
(10.4) +L vs  
12 (4.0) -L;  
invasive SPMs: 
23 (7.5) +L vs  
9 (3.0) –L 
13  
(4.2) +L vs  
5 (1.7) -L 
10  
(3.3) +L vs  
4 (1.3) -L 
NR IR per 100 patient-y: 3.1 +L vs 1.2 -L  
(P = 0.002) 
McCarthy 
et al. [19] 
Lenalidomide vs 
placebo as 
maintenance after 
ASCT 
2005–2009 460  
(231 +L vs  
229 -L) 
18  
(7.8) +L vs  
6 (2.6) -L 
8  
(3.5) +L vs  
1 (0.4) -L 
10  
(4.3) +L vs  
5 (2.2) -L 
HMs: 28 mo +L  
vs 30 mo -L; 
STs: 15 mo +L  
vs 21 mo -L 
Overall, cumulative risk of SPMs was 
greater in +L than in placebo group  
(P = 0.0008) 
Palumbo 
et al. [17] 
MPR-R vs MPR 
vs MP in patients 
not eligible for 
ASCT 
2007–2008 459  
(152 MPR-R vs 
153 MPR vs  
154 MPT) 
12  
(7.9) MPR-R vs  
9 (5.9) MPR vs  
4 (2.6) MPT 
7  
(4.6) MPR-R 
vs 5 (3.3) 
MPR vs  
1 (0.7) MPT 
5  
(3.3) MPR-R 
vs 4 (2.6) 
MPR vs  
3 (1.9) MPT 
NR  IR/100 patient-y: 1.4% for MPR-R vs 
2.1% for MPR vs 0.7% for MP 
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Palumbo 
et al. [65] 
RD followed by 
ASCT vs MPR, 
then lenalidomide 
maintenance vs 
no maintenance 
2007–2009  
(51.2 mo) 
402  
(273 randomized 
to consolidation: 
141 ASCT vs 132 
MPR; 251 
randomized to L 
maintenance vs 
no maintenance: 
57 ASCT +L vs 59 
ASCT -L, and 59 
MPR +L vs 56 
MPR -L) 
11  
(2.7) 
1  
(0.2) 
10  
(2.5)  
1 during 
induction;  
5 in +L vs  
4 in -L 
maintenance 
arm 
NR   
Benboubker 
et al. [66] 
RD until 
progression vs  
RD 18 cycles vs 
MPT in patients 
not eligible for 
ASCT 
2008–2011  
(37 mo) 
1613  
(535 RD, 541 RD 
18 cycles,  
547 MPT) 
All SPMs 
(including 
NMST): 37  
(7) RD until 
progression vs 
44 (8.1) RD 18 
cycles vs 47 
(8.7) MPT; 
Invasive SPMs: 
17 (3.2) RD until 
progression vs 
30 (5.6) RD 18 
cycles vs 27 
(5.0) MPT 
2  
(0.4) RD 
until 
progression 
vs 2 (0.4) 
RD 18 
cycles vs 12 
(2.2) MPT 
(all MDS/ 
AML) 
15 (2.8) RD 
until 
progression 
vs 29 (5.4) 
RD 18 
cycles vs 15 
(2.8) MPT 
NR IR/100 person-y (CI):  
ALL SPMs: RD until progression 2.76  
(2–3.81) vs RD 18 cycles 3.33  
(2.48–4.48) vs MPT 3.68 (2.76–4.89): 
HMs: RD until progression 0.14  
(0.04–058) vs RD 18 cycles 0.14  
(0.04–058) vs MPT 0.91 (0.52–1.61);  
STs: RD until progression: 1.09  
(0.66–1.81) vs RD 18 cycles 2.15  
(1.49–3.09) vs MPT 1.15 (0.69–1.90);  
NMST: RD until progression 1.62  
(1.07–2.46) vs RD 18 cycles 1.25  
(1.78–2.02) vs MPT 1.62 (1.05–2.48).  
Overall, IR of incidence of hematologic 
SPMs was significantly lower with RD 
(0.4%) vs MPT (2.2%). 
Jones 
et al. [37] 
CRD vs CTD 
(induction); 
bortezomib vs  
no consolidation; 
lenalidomide- 
based 
maintenance vs 
no maintenancea 
2010–2015 2745 69  
(2.5) 
8  
(0.3)   
MDS, AML, 
CML, HD  
61  
(2.2) 
including 
NMST 
All SPMs: 15.6 mo 
(range 1.2–42.5); 
HMs: 18.2 mo  
(5.9–42.5)  
Cumulative incidence (95% CI) of all 
SPMs: 0.65% (0.35, 0.97), 1.84%  
(1.26, 2.41), and 3.41% (2.49, 4.43) at  
1, 2, and 3 years, respectively 
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Stewart  
et al. [67] 
MPT-T vs MPR-R 2008–2011  
(40.7 mo) 
306  
(298 received 
randomized 
treatment:  
148 MPT-T vs  
150 MPR-R) 
All SPMs: 32 
(10.7); 18 MPT-
T (12.2) vs 14 
MPR-R (9.3) 
excluding 
NMST: all 
SPMs: 22 (7.4);  
14 MPT-T (9.5) 
vs 8 MPR-R 
(5.3) 
14  
(4.7) 
10 MPT-T 
(6.7) vs 4 
(2.6) MPR-R 
18, including 
9 NMST (6); 
invasive: 8 
(2.7): 4 (2.7) 
MPT-T vs 4 
(2.7) MPR-R 
NR IR/100 patient-y: total 4.06; MPT-T 
4.56, vs MPR-R 3.56, excluding NMST: 
total 2.74; MPT-T 3.47 vs MPR-R 2.01  
Zweegman 
et al. [68] 
MPT-T vs MPR-R 2009–2012 560  
(280 MPT-T vs  
280 MPR-R) 
Invasive, 
excluding 
NMST: 38 (6.8) 
9  
(1.6) 
AML/MDS:  
3 (0.5) MPT-
T vs 6 (1.1) 
MPR-R 
29  
(5.2) 18 (3.2) 
MPT-T vs 11 
(2.0) MPR-R 
NR IR/100 patient-y: 3.3 (MPT-T) vs 2.4 
(MPR-R), P = 0.33 
Palumbo  
et al. [69] 
VMPT-VT vs VMP 2006–2009  
(54 mo) 
511  
(254 VMPT-VT vs  
257 VMP) 
0.9% VMPT-VT 
vs 1.5% VMP 
NR NR NR   
San Miguel 
et al. [70] 
VMP vs MP 2004–2006  
(60.1 mo) 
682 enrolled; 655 
analyzed for 
SPMs  
(327 VMP vs  
328 MP) 
19  
(5.8) VMP vs 13 
(4.0) MP 
3  
(0.9) VMP vs 
3 (0.9) MP 
16  
(4.9) VMP vs 
10 (3.0) MP 
HMs: 18–48 mo in 
the VMP arm,  
1–35 mo in the 
MP arm;  
STs: 1–56 mo  
(22.7 median 
VMP and 30,3 
MP) 
Similar exposure-adjusted incidence 
rates: 0.017 VMP vs 0.013 MP per 
patient-y 
Brioli  
et al. [71] 
VTD vs TD 
followed by ASCT 
2006–2008  
(73 mo) 
299  
(148 VTD vs  
151 TD) 
25  
(8.3); 5% VTD 
vs 11% TD 
7  
(2.3%);  
1.3% VTD vs 
3.2% TD 
18  
(6.0%);  
3.8% VTD vs 
7.8% TD 
36 mo IR for total population 1% at 1 y and 
9.9% at 6 y 
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ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; CI, confidence interval; CML, chronic myeloid leukemia; CRD, 
cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; HD, Hodgkin’s disease, HM: hematologic malignancy; IMWG, 
International Myeloma Working Group; IR, incidence rate; +L lenalidomide exposure; -L no lenalidomide exposure; MDS, myelodysplastic syndromes; MM, multiple myeloma; mo, 
months; MP, melphalan + prednisone; MPR, MP + lenalidomide (revlimid); MPR-R, MPR followed by lenalidomide maintenance; MPT, melphalan + prednisone + thalidomide; MPT-T, 
MPT folloved by thalidomide maintenance; NMST, non-melanoma skin tumors; NR, not reported; RD, lenalidomide + dexamethasone; SPM, secondary primary malignancy; ST, solid 
tumor; TD, thalidomide + prednisone; VGPR, very good partial response according to IMWG criteria; VMP, bortezomib + melphalan + prednisone; VMPT-VT, bortezomib + melphalan + 
prednisone + thalidomide followed by bortezomib + thalidomide maintenance; VTD, bortezomib + thalidomide + prednisone; y, years. 
aAge-adjusted CRD vs CTD as induction; consolidation with bortezomib vs no consolidation (before ASCT in younger patients) if response < VGPR; lenalidomide-based maintenance vs 
no maintenance. 
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supplementary appendix – panel recommendations 
 
what is the ‘true’ risk of SPM development in patients with MM? 
panel recommendations  
Well-designed population-based studies suggest that second primary malignancy (SPM) risk 
in multiple myeloma (MM) is low, and is partially related to the lengthening survival of 
patients with MM. The Panel recommends SPM risk evaluation in individual patients, 
according to patient-, disease-, and treatment-related factors, and stresses the need for 
accurate records of additional and systematic data gathering to determine the incidence and 
types of SPMs in patients currently receiving treatment in MM clinical trials and in the real-
world setting. Ongoing clinical trial protocols should be amended to include enhanced 
monitoring and precise measurement of secondary cancers, including non-invasive 
neoplasms, which may represent a proof-of-principle of the cancer-promoting activity of 
specific treatments. New prospective trials with next-generation novel agents should also 
include SPMs as an ‘a priori’ well-defined endpoint. Additionally, the Panel recommends that 
careful monitoring for SPMs should be integral to these trials.  
 
Future clinical investigations and real-life treatments should include bone marrow 
examinations with cytogenetic analyses (including fluorescence in situ hybridization [1], if 
necessary) at baseline. Additionally, prospective population‐based studies, gathering 
information on the baseline characteristics and treatment of individual patients, should report 
SPM data that could provide important clinical and scientific information.  
 
SPM incidence rates should be adjusted for person-years at risk (i.e. rate per 100 
person/years), to reduce the possibility of SPM risk overestimation as a result of longer 
patient survival under current treatment regimens. Previous individual and family history of 
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malignancy should also be investigated. Finally, it will be important to collect data about time 
to development, clinical and biologic characteristics, prognosis, and the natural history of 
SPMs observed in future trials of novel agents. For MDS/AML in particular, efforts should be 
made to record the types of cytogenetic and molecular changes taking place, in order to 
evaluate whether they present with a pattern different from that observed in cases caused by 
cytotoxic chemotherapy or radiation.  
 
In the light of available data, physicians should be extremely cautious when evaluating 
patient symptoms or findings indicative of a second malignancy. Specific routine screening 
for solid tumors, with the exception of those suggested for the general population, is not 
recommended in this setting. However, diagnostic measures that would aid the detection of 
a suspected SPM during routine clinical work-up should be considered, case by case, 
among long-term MM survivors. Similarly, despite the observed increased tumor risk among 
individuals with monoclonal gammopathy of undetermined significance (MGUS) [2], a 
premalignant condition thought almost always to precede the development of MM [3, 4], the 
Panel does not recommend additional screening for malignancies in such patients, with the 
exception of the follow-up recommended in the current International Myeloma Working 
Group (IMWG) guidelines [5], and the regular age-appropriate screening tests recommended 
for the general population. However, where unexplained abnormalities in blood counts arise, 
bone marrow examinations with cytogenetic analyses (or fluorescence in situ hybridization, if 
necessary) are recommended to investigate potential hematologic SPMs. Finally, a careful 
review process should be considered an important component of future clinical trials, to 
accurately assess the impact of treatment on SPM development, and to prevent false 
inflation of SPM rates. 
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what are the possible host- and disease-related risk factors for 
SPMs in patients with MM? 
panel recommendations  
While several host- and disease-related factors may contribute to the predisposition of 
patients with MM to SPMs, host genetics are likely to present an opportunity to define an 
individual’s susceptibility to SPM development. The Panel recommends the collection of 
biologic samples from all MM patients included in clinical trials and, when possible, 
encountered in clinical practice, and their storage for genetic analysis. Ideally, samples 
should yield DNA for genomic analysis or, better still, RNA for gene expression profiling. 
Collection of germline and tumor-related material, and re-banking of biologic samples during 
the course of the disease, are also recommended. Next-generation sequencing genomic 
studies aimed at identifying genetic profiles associated with increased SPM risk should be 
planned. Genomic analysis will be particularly important in the context of patients with lower-
risk MM or smoldering myeloma, as these patients have a longer life expectancy and would 
therefore benefit most from a risk-adaptive therapy approach. Indeed, identifying patients at 
risk for SPMs at the time of diagnosis of MM would enable personalized treatment and post-
therapy surveillance options to minimize this risk. 
 
do older and novel therapies increase SPM risk in MM? 
panel recommendations  
Based on the available evidence, the potential risk of SPMs in MM should not alter the 
current therapeutic decision-making process. Data regarding the use of autologous stem cell 
transplantation (ASCT) in MM are reassuring and, in the light of very recent clinical findings 
strongly confirming the benefits of this procedure, first-line therapeutic approaches in eligible 
MM patients should always include ASCT conditioned with high-dose intravenous 
melphalan. 
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While there appears to be no doubt that the use of bortezomib, either in the transplant 
setting or in elderly patients, is not associated with an increased risk of SPMs, the clinical 
implications of the increased SPM risk observed with lenalidomide therapy need to be 
carefully considered alongside the benefits of treatment. For most patients, MM remains an 
incurable malignancy and, on average, the risk of dying is substantially higher than the risk 
of developing a SPM. The benefits of lenalidomide therapy versus older, standard therapies 
for active MM in the first-line and relapsed settings are well documented, and include better 
and deeper responses, longer progression-free survival, and longer overall survival. In 
contrast, rates of mortality due to myeloma progression or treatment-related adverse events 
(mainly infection and cardiovascular events) in patients treated with lenalidomide are 
markedly higher than those due to SPMs. With this in mind, the Panel believes that, for the 
approved indication of lenalidomide in the treatment of relapsed MM, the benefits of 
treatment clearly outweigh any risk of SPMs. Similarly, in front-line therapy without 
concurrent oral melphalan, regimens such as lenalidomide plus dexamethasone (or 
alternatives such as cyclophosphamide or alkylating-free combinations) remain safe and 
effective options that should be considered for patients with MM, instead of oral melphalan in 
combination with lenalidomide.  
 
In the maintenance setting, the risk/benefit analysis for lenalidomide is more complex. 
In particular, with the important exception of high-dose melphalan employed as a 
conditioning regimen for ASCT, prolonged administration of lenalidomide where there is 
antecedent melphalan exposure should generally be avoided. Data regarding patients 
receiving lenalidomide for more than 2 years are limited, and do not present a clear picture 
of the impact of treatment duration (and, presumably, of cumulative dose or schedule) on 
SPM risk. Long-term follow-up of a greater number of patients receiving lenalidomide for 
longer than 2 years is needed for reassurance regarding this point, particularly as 
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lenalidomide is still given until disease progression. Indeed, in circumstances where the 
overall survival benefit of maintenance therapy is not well established, the risks versus any 
possible benefits should still be considered carefully. For MM patients with other cancers, the 
few available data would suggest that lenalidomide, if indicated, should not be withheld 
because of concerns about subsequent cancer, irrespective of a prior cancer diagnosis. 
However, alternative therapies, if available, should be considered. 
 
The Panel recommends that all patients initiating lenalidomide maintenance undergo a 
baseline bone marrow examination with cytogenetics to ensure there is no overt evidence of 
dysplasia or concerning cytogenetic abnormalities. There should also be a low threshold for 
a careful bone marrow analysis, with karyotyping for patients with unexplained cytopenias 
that persist despite lenalidomide withdrawal. Finally, the role of multiple salvage treatments 
in contributing to development of SPMs remains to be determined.  
 
The above issues should be adequately addressed through appropriate discussion with 
the patient about the potential increased risk for SPMs. Informed decisions regarding 
therapy should be made in conjunction with the patient, bearing in mind current knowledge 
about treatment-associated risks and benefits. Physicians should remain well informed about 
the latest data on the risk of SPMs in MM. 
51 
 
references 
1. Rollison DE, Komrokji R, Lee J-H et al. Subsequent Primary Malignancies Among 
Multiple Myeloma Patients Treated with or without Lenalidomide. Blood (ASH Meeting 
Abstracts) 2014; 124: Abstract 2129. 
 
2. Mailankody S, Pfeiffer RM, Kristinsson SY et al. Risk of acute myeloid leukemia and 
myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). 
Blood 2011; 118: 4086–4092. 
 
3. Landgren O, Kyle RA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined 
significance (MGUS) consistently precedes multiple myeloma: a prospective study. 
Blood 2009; 113: 5412–5417. 
 
4. Weiss BM, Abadie J, Verma P et al. A monoclonal gammopathy precedes multiple 
myeloma in most patients. Blood 2009; 113: 5418–5422. 
 
5. van de Donk NW, Palumbo A, Johnsen HE et al. The clinical relevance and 
management of monoclonal gammopathy of undetermined significance and related 
disorders: recommendations from the European Myeloma Network. Haematologica 
2014; 99: 984–996. 
 
